Skip to main content
SpringerLink
Log in

Enzyme replacement and enhancement therapies for lysosomal diseases

  • Published:
Journal of Inherited Metabolic Disease

Abstract

Summary: Although first suggested by de Duve in 1964, enzyme replacement therapy (ERT) for lysosomal storage diseases did not become a reality until the early 1990s when its safety and effectiveness were demonstrated in type 1 Gaucher disease. Today, ERT is a reality for Gaucher disease, Fabry disease and mucopolysaccharidosis type I (MPS I), and clinical trials with recombinant human enzymes are ongoing in Pompe disease, MPS II and MPS VI, and are about to begin in Neimann–Pick B disease. In addition to ERT, enzyme enhancement therapy (EET) offers a novel therapeutic strategy to increase the residual function of mutant proteins. EET employs small molecules as 'pharmacological chaperones' to rescue misfolded and/or unstable mutant enzymes or proteins that have residual function. EET also offers the possibility of treating neurodegenerative lysosomal disorders since these small therapeutic molecules may cross the blood–brain barrier. The current status of ERT and the prospects for EET for lysosomal storage diseases are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278: 40911–40916.

    Article  PubMed  CAS  Google Scholar 

  • Amalfitano A, Bengur AR, Morse RP, et al (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3: 132–138.

    Article  PubMed  CAS  Google Scholar 

  • Amaral MD (2004) CFTR and chaperones. J Mol Neurosci 23: 41–48.

    Article  PubMed  CAS  Google Scholar 

  • Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding disease. Nature 426: 905–909.

    Article  PubMed  CAS  Google Scholar 

  • Asano N, Ishii S, Kizu H, et al (2000) In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267: 4179–4186.

    Article  PubMed  CAS  Google Scholar 

  • Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 87: 1913–1916.

    Article  PubMed  CAS  Google Scholar 

  • Barton NW, Brady RO, Dambrosia JM, et al (1991) Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464–1470.

    Article  PubMed  CAS  Google Scholar 

  • Beck M, Wraith JE, Clarke AA, et al (2002) A phase 3 study of rhIDUA enzyme therapy for MPS I. J Inherit Metab Dis 25: 120.

    Google Scholar 

  • Bijvoet AG, Van Hirtum H, Kroos MA, et al (1999) Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 8: 2145–2153.

    Article  PubMed  CAS  Google Scholar 

  • Bonten EJ, Toy JN, Mann L, et al (2002) Effective enzyme replacement therapy of murine galactosialidosis using insect cell-expressed PPCA and neuraminidase. Am J Hum Genet 71: 420.

    Google Scholar 

  • Brady RO, Barton NW (1991) Enzyme replacement therapy for type 1 Gaucher disease. In Desnick RJ, ed. Treatment of Genetic Diseases. New York: Churchill Livingstone, 153–168.

    Google Scholar 

  • Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS (1974) Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 291: 989–993.

    Article  PubMed  CAS  Google Scholar 

  • Brady RO, Barranger JA, Gal AE, Pentchev PG, Furbish FS (1980) Status of enzyme replacement therapy for Gaucher disease. In Desnick RJ, ed. Enzyme Therapy in Genetic Disease: 2. New York: Alan R. Liss, 361–368.

    Google Scholar 

  • Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ (1996) Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1: 117–125.

    Article  PubMed  CAS  Google Scholar 

  • Burrows JA, Willis LK, Perlmutter DH (2000) Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in α1-ATdeficiency. Proc Natl Acad Sci USA 97: 1796–1801.

    Article  PubMed  CAS  Google Scholar 

  • Byers S, Crawley AC, Brumfield LK, Nuttall JD, Hopwood JJ (2000) Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr Res 47: 743–749.

    PubMed  CAS  Google Scholar 

  • Cabral CM, Liu Y, Sifers RN (2001) Dissecting glycoprotein quality control in the secretory pathway. Trends Biochem Sci 26: 619–624.

    Article  PubMed  CAS  Google Scholar 

  • De Schoenmakere G, Chauveau D, Grunfeld JP (2003) Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18: 33–35.

    Article  PubMed  CAS  Google Scholar 

  • Cantz M, Kresse H (1974) Sandhoff disease: defective glycosaminoglycan catabolism in cultured fibroblasts and its correction by β-N-acetylhexosaminidase. Eur J Biochem 47: 581–590.

    Article  PubMed  CAS  Google Scholar 

  • Carrell RW, Lomas DA (2002) α1-Antitrypsin deficiency—a model for conformational diseases. N Engl J Med 346: 45–53.

    Article  PubMed  CAS  Google Scholar 

  • Clarke LA, Wraith JE, Beck M, et al (2003) Aldurazyme (iduronidase) enzyme replacement theapy for MPS I: 48-week extension data. Am J Hum Genet 73: 623.

    Google Scholar 

  • Cohen FE, Kelly JW (2003) Therapeutic approaches to protein-misfolding disease. Nature 426: 905–909.

    Article  PubMed  CAS  Google Scholar 

  • de Duve C (1964) From cytases to lysosomes. Fed Proc 23: 1045.

    CAS  Google Scholar 

  • Desnick RJ (ed.) (1980) Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss.

    Google Scholar 

  • Desnick RJ (1991) Treatment of Genetic Diseases. New York: Churchill Livingstone.

    Google Scholar 

  • Desnick RJ, Bernlohr RW, Krivit W, eds (1973) Enzyme Therapy in Genetic Diseases, Birth Defects. Original Article Series. New York: The National Foundation.

    Google Scholar 

  • Desnick RJ, Thorpe SR, Fiddler MB (1976) Toward enzyme therapy for lysosomal storage diseases. Physiol Rev 56: 57–99.

    PubMed  CAS  Google Scholar 

  • Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn.; New York: McGraw-Hill, 3733–3774.

    Google Scholar 

  • Desnick RJ, Brady R, Barranger J, et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338–346.

    PubMed  Google Scholar 

  • Dobrenis K, Joseph A, Rattazzi MC (1992) Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin. Proc Natl Acad Sci USA 89: 2297–2301.

    Article  PubMed  CAS  Google Scholar 

  • Doebber TW, Wu MS, Bugianesi RL, et al (1982) Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase. J Biol Chem 257: 2193–2199.

    PubMed  CAS  Google Scholar 

  • Du H, Schiavi S, Levine M, et al (2001) Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet 10: 1639–1648.

    Article  PubMed  CAS  Google Scholar 

  • Ellgaard L, Molinari M, Helenius A (1999) Setting the standards: quality control in the secretory pathway. Science 286: 1882–1888.

    Article  PubMed  CAS  Google Scholar 

  • Eng CM, Banikazemi M, Gordon R, et al (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711–722.

    Article  PubMed  CAS  Google Scholar 

  • Eng CM, Guffon N, Wilcox WR, et al (2001b) Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9–16.

    Article  PubMed  CAS  Google Scholar 

  • Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Medicine 5: 112–115.

    Article  PubMed  CAS  Google Scholar 

  • Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24: 355–360.

    Article  PubMed  CAS  Google Scholar 

  • Fewell SW, Travers KJ, Weissman JS, Brodsky JL (2001) The action of molecular chaperones in the early secretory pathway. Annu Rev Genet 35: 149–191.

    Article  PubMed  CAS  Google Scholar 

  • Fleischer LD, Gaull GE (1980) Enzyme manipulation by specific megavitamin therapy. In Desnick RJ, ed. Enzyme Therapy in Genetic Diseases: 2. New York: Alan R. Liss, 239–268.

    Google Scholar 

  • Frustaci A, Chimenti C, Ricci R, et al (2001) Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345: 25–32.

    Article  PubMed  CAS  Google Scholar 

  • Furbish FS, Steer CJ, Kreet NL, Barranger JA (1981) Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 673: 425–434.

    PubMed  CAS  Google Scholar 

  • Gelman MS, Kopito RR (2002) Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. J Clin Invest 110: 1591–1597.

    Article  PubMed  CAS  Google Scholar 

  • Ghosh P, Dahms NM, Kornfeld S (2003) Mannose-6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4: 202–212.

    Article  PubMed  CAS  Google Scholar 

  • Grabowski GA, Barton NW, Pastores G, et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33–39.

    PubMed  CAS  Google Scholar 

  • Grabowski GA, Leslie N, Wenstrup R (1998) Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 12: 115–133.

    Article  PubMed  CAS  Google Scholar 

  • Guffon N, Fouilhoux A (2004) Clinical benefit in Fabry patients given enzyme replacement therapy-a case series. J Inherit Metab Dis, in press.

  • Harmatz P, Whitley CB, Waber L, et al (2002) A Phase I/II study of enzyme replacement therapy (ERT) for mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome): 48 week progress report. Am J Hum Genet 71: 582.

    Google Scholar 

  • Harmatz P, Ketteridge D, Steiner R, et al (2003) A phase II open-label clinical study of efficacy and safety of recominant human N-acetylgalactosamine 4-sulfatase (rhASB) enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy sydrome). Am J Hum Genet 73: 623.

    Google Scholar 

  • Harmatz P, Whitley CB, Waber L, et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144: 574–580.

    Article  PubMed  CAS  Google Scholar 

  • Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93: 1288–1292.

    PubMed  CAS  Google Scholar 

  • Ioannou YA, Bishop DF, Desnick RJ (1992) Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J Cell Biol 119: 1137–1150.

    Article  PubMed  CAS  Google Scholar 

  • Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ (2001) Fabry disease: preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68: 14–25.

    Article  PubMed  CAS  Google Scholar 

  • Johnson WG, Desnick RJ, Long DM, et al (1973) Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. In Desnick RJ, Bernlohr RW, Krivit W, eds. Enzyme Therapy in Genetic Diseases, Birth Defects. Original Article Series. New York: The National Foundation, 120–124.

    Google Scholar 

  • Kakkis ED, McEntee MF, Schmidtchen A, et al (1996) Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156–167.

    Article  PubMed  CAS  Google Scholar 

  • Kakkis E, Muenzer J, Tiller G, et al (1998) Recombinant α-L-iduronidase replacement therapy in mucopolysaccharidosis I: results of a human clinical trial. Am J Hum Genet 63 (supplement): A25.

    Google Scholar 

  • Kakkis ED, Muenzer J, Tiller GE, et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182–188.

    Article  PubMed  CAS  Google Scholar 

  • Kikuchi T, Yang HW, Pennybacker M, et al (1998) Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 101: 827–833.

    PubMed  CAS  Google Scholar 

  • Kishnani P, Voit T, Nicolino M, et al (2002) Treatment of classical infantile Pompe disease (CIPD) with recombinant human acid α-glucosidase (rhGAA): preliminary 6 month data from a Phase 2 study. Am J Hum Genet 71: 582.

    Google Scholar 

  • Kornfeld S (1990) Lysosomal enzyme targeting. Biochem Soc Trans 18: 367–374.

    PubMed  CAS  Google Scholar 

  • Lee K, Jin X, Zhang K, et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13: 305–313.

    Article  PubMed  Google Scholar 

  • Linthorst GE, Blom D, Specijer D, Hollak CEM, Awrts JMFG (2002) Therapy for Fabry disease; comparison of agalsidase alpha and beta enzyme preparations. J Inherit Metab Dis 25: A115.

    Google Scholar 

  • Loo TW, Clarke DM (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272: 709–712.

    Article  PubMed  CAS  Google Scholar 

  • Matsuda J, Suzuki O, Oshima A, et al (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci USA 100: 15912–15917.

    Article  PubMed  CAS  Google Scholar 

  • Miranda SR, He X, Simonaro CM, et al (2000) Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J 14: 1988–1995.

    Article  PubMed  CAS  Google Scholar 

  • Molinari M, Calanca V, Galli C, Lucca P, Paganetti P (2003) Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle. Science 299: 1397–1400.

    Article  PubMed  CAS  Google Scholar 

  • Morello JP, Petaja-Repo UE, Bichet DG, Bouvier M (2000a) Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci 21: 466–469.

    Article  PubMed  CAS  Google Scholar 

  • Morello JP, Salahpour A, Laperriere A, et al (2000b) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105: 887–895.

    PubMed  CAS  Google Scholar 

  • Muenzer J, Towle D, Calikoglu M, McCandlless S (2002) A Phase I/II clinical study evaluating the safety and clinical activity of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Am J Hum Genet 71: 582.

    Google Scholar 

  • Muenzer J, Calikoglu M, Towle D, McCandlless S, Kimura A (2003) The one year experience of enzyme replacement therapy for mucopolysaccharidosis II (Hunter syndrome). Am J Hum Genet 73: 623.

    Google Scholar 

  • Nakao S, Takenaka T, Maeda M, et al (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333: 288–293.

    Article  PubMed  CAS  Google Scholar 

  • O'Brien JS, Miller AL, Loverde AW, Veath ML (1973) Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Science 181: 753–755.

    PubMed  Google Scholar 

  • Oda Y, Hosokawa N, Wada I, Nagata K (2003) EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. Science 299: 1394–1397.

    Article  PubMed  CAS  Google Scholar 

  • Okumiya T, Ishii S, Takenaka T, et al (1995) Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem Biophys Res Commun 214: 1219–1224.

    Article  PubMed  CAS  Google Scholar 

  • Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type I: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: 408–416.

    PubMed  CAS  Google Scholar 

  • Petaja-Repo UE, Hogue M, Bhalla S, et al (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J 21: 1628–1637.

    Article  PubMed  CAS  Google Scholar 

  • Porter MT, Fluharty AL, Kihara H (1971) Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 172: 1263–1265.

    PubMed  CAS  Google Scholar 

  • Powell K, Zeitlin PL (2002) Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv Drug Deliv Rev 54: 1395–1408.

    Article  PubMed  CAS  Google Scholar 

  • Princiotta MF, Finzi D, Qian SB, et al (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18: 343–354.

    Article  PubMed  CAS  Google Scholar 

  • Rattazzi MC, Dobrenis K (1991) Enzyme replacement: overview and prospects. In Desnick RJ, ed. Treatment of Genetic Diseases. New York: Churchill Livingstone, 131–152.

    Google Scholar 

  • Richards SM, Olson TA, McPherson JM (1993) Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82: 1402–1409.

    PubMed  CAS  Google Scholar 

  • Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM (1999) Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93: 2081–2088.

    PubMed  CAS  Google Scholar 

  • Rubenstein RC, Egan ME, Zeitlin PL (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing deltaF508-CFTR. J Clin Invest 100: 2457–2465.

    Article  PubMed  CAS  Google Scholar 

  • Sabatini DD, Adesnik MB (2001) The biogenesis of membranes and organelles. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 475–484.

    Google Scholar 

  • Sands MS, Vogler CA, Ohlemiller KK, et al (2001) Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 276: 43160–43165.

    Article  PubMed  CAS  Google Scholar 

  • Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271: 635–638.

    Article  PubMed  CAS  Google Scholar 

  • Sawkar AR, Cheng WC, Beutler E, et al (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99: 15428–15433.

    Article  PubMed  CAS  Google Scholar 

  • Schiffmann R, Murray GJ, Treco D, et al (2000) Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97: 365–370.

    Article  PubMed  CAS  Google Scholar 

  • Schiffmann R, Kopp JB, Austin HA 3rd, et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743–2749.

    Article  PubMed  CAS  Google Scholar 

  • Schubert U, Anton LC, Gibbs J, et al (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404: 770–774.

    Article  PubMed  CAS  Google Scholar 

  • Shull RM, Kakkis ED, McEntee MF, et al (1994) Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 91: 12937–12941.

    Article  PubMed  CAS  Google Scholar 

  • Tager JM, Hooghvinkel GJM, Daems WT (1974) Enzyme Therapy in Lysosomal Storage Diseases. Amsterdam: North-Holland.

    Google Scholar 

  • Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296: 1991–1995.

    Article  PubMed  CAS  Google Scholar 

  • Treacy EP, Valle D, Scriver CR (2001) Treatment of genetic disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 175–191.

    Google Scholar 

  • Tropak MB, Reid SP, Guiral M, et al (2004) Pharmacological enhancement of betahexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J Biol Chem 279: 13478–13487.

    Article  PubMed  CAS  Google Scholar 

  • Van den Hout H, Reuser A, Vulto A, et al (2000a) First clinical test with recombinant human α-glucosidase from rabbit milk shows therapeutic effect in Pompe disease. Am J Hum Genet 67(supplement 2): 6.

    Google Scholar 

  • Van den Hout H, Reuser AJ, Vulto AG, et al (2000b) Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 356: 397–398.

    Article  PubMed  CAS  Google Scholar 

  • Van den Hout JM, Reuser AJ, de Klerk JB, et al (2001) Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 24: 266–274.

    Article  PubMed  CAS  Google Scholar 

  • Van den Hout JM, Kamphoven JH, Winkel LP, et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: 448–457.

    Article  Google Scholar 

  • van der Ploeg AT, Winkel LPF, van Diggelen OP, et al (2002) Preliminary findings in patients with late onset Pompe's disease treated with recombinant human α-glucosidase from rabbit milk. J Inherit Metab Dis 25: 118.

    Google Scholar 

  • Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT (1996) High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci USA 93: 65–70.

    Article  PubMed  CAS  Google Scholar 

  • Vogler C, Levy B, Galvin NJ, et al (1999) Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 45: 342–348.

    Google Scholar 

  • von Scheidt W, Eng CM, Fitzmaurice TF, et al (1991) An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324: 395–399.

    Article  PubMed  CAS  Google Scholar 

  • von Specht BU, Geiger B, Arnon R, et al (1979) Enzyme replacement in Tay-Sachs disease. Neurology 29: 848–854.

    PubMed  CAS  Google Scholar 

  • Waldek S (2003) PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 348: 1186–1187.

    Article  PubMed  Google Scholar 

  • Weidemann F, Breunig F, Beer M, et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108: 1299–1301.

    Article  PubMed  CAS  Google Scholar 

  • Weinreb NJ, Charrow J, Andersson HC, et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112–119.

    Article  PubMed  CAS  Google Scholar 

  • Welch WJ, Brown CR (1996) Influence of molecular and chemical chaperones on protein folding. Cell Stress Chaperones 1: 109–115.

    Article  PubMed  CAS  Google Scholar 

  • Welch WJ, Howard M (2000) Antagonists to the rescue. J Clin Invest 105: 853–854.

    PubMed  CAS  Google Scholar 

  • Wilcox WR, Banikazemi M, Guffon N, et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet, in press.

  • Winkel LP, Van den Hout JM, Kamphoven JH, et al (2004) Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 55: 495–502.

    Article  PubMed  CAS  Google Scholar 

  • Wraith JE, Clarke LA, Beck M, et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (Laronidase). J Pediatr 144: 581–588.

    Article  PubMed  CAS  Google Scholar 

  • Wu Y, Swulius MT, Moremen KW, Sifers RN (2003) Elucidation of the molecular logic by which misfolded α1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci USA 100: 8229–8234.

    Article  PubMed  CAS  Google Scholar 

  • Yewdell JW (2001) Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 11: 294–297.

    Article  PubMed  CAS  Google Scholar 

  • Young E, Chatterton C, Vellodi A, Winchester B (1997) Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Dis 20: 595–602.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Genetics, Mount Sinai School of Medicine of New York University, New York, NY, 10029, USA E-mail: rjdesnick@mssm.edu

    R. J. Desnick

Authors
  1. R. J. Desnick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desnick, R.J. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27, 385–410 (2004). https://doi.org/10.1023/B:BOLI.0000031101.12838.c6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BOLI.0000031101.12838.c6

Keywords

Search

Navigation